Atopic Dermatitis: Treating Beyond What You See

For many clinicians, escalation in AD isn’t tied to a single threshold anymore. It’s a judgment call, shaped by what the disease is doing over time and how much it’s affecting the patient’s day-to-day life. As familiarity with biologics has grown, along with reassuring safety data and broader indications, there’s been a noticeable shift toward earlier use, particularly with therapies targeting type 2 inflammation. This portion of the Biologics Innovation Experience examines how that shift is playing out in practice and the ways it’s changing when and how we intervene.

Rethinking Psoriatic Disease

Treating psoriatic disease means paying attention to what’s visible on the skin and what may be unfolding beneath it. With the expansion of deucravacitinib into psoriatic arthritis, the question is no longer just which therapy improves plaques. It’s how we identify patients earlier, think about joint risk in a dermatology setting, and make decisions for patients who don’t quite fit our usual categories. Across the experience, faculty translate this into practice by exploring how often psoriatic arthritis is missed or delayed, which patients begin to stand out, where an oral TYK2 inhibitor may fit, and what remains unresolved in day-to-day care.

Early Treatment of HS With Secukinumab

Sekukinumab Long-Term Phase 3 Data